News from NCI about COVID-19

• 

  NCI, NIBIB award contracts to develop innovative digital health technologies for COVID-19

  NCI and the National Institute of Biomedical Imaging and Bioengineering have awarded seven contracts to develop digital health solutions, like smartphone apps, wearable devices, and software, that help address the COVID-19 pandemic.

• 

  NCI Initiatives on the Human Immune Response to SARS-CoV-2

  In this NCI Bottom Line blog post, NCI Deputy Directors Dr. Dinah Singer and Dr. Doug Lowy provide an update on SeroNet, including the Centers of Excellence and serological sciences projects, the SeroNet Serology Lab, Serological Sciences Capacity Building Centers, and a SeroNet Coordinating Center.

• 

  Responding to Coronavirus, Cancer Researchers Reimagine Clinical Trials

  In response to COVID-19, cancer researchers are making changes to clinical trials to ensure patient safety and protect the integrity of their work. This Cancer Currents blog post reports that some changes will likely continue into the future.

• 

  NCI Seeks Applications for SeroNet COVID-19 Research

  NCI Deputy Director Dr. Dinah Singer describes the recently launched Serological Sciences Network (SeroNet) and elaborates on funding opportunities for the initiative in this NCI Bottom Line blog post.

• 

  Study identifies potential approach to treat severe respiratory distress in patients with COVID-19

  This NCI Media Availability describes early data from a clinical study that suggest that treatment with the cancer drug acalabrutinib provided clinical benefit to a small group of patients with severe COVID-19.

• 

  How Does COVID-19 Affect People with Cancer? NCCAPS Will Help Find Out

  NCI has launched the COVID-19 in Cancer Patients Study (NCCAPS), which will help answer questions about COVID-19’s impact on cancer patients. The study is now open to adults and will later be expanded to include children.

• 

  Cancer Research in the Era of COVID-19

  In this NCI Bottom Line blog post, NCI Deputy Director Dinah Singer, Ph.D., highlights examples of how NCI continues to make progress in cancer research during the era of COVID-19 and provides details on how NCI, working with NIH, has implemented new flexibilities for the cancer research community during this crisis.

• 

  NCI Part of Federal Effort to Evaluate Antibody Tests for Novel Coronavirus

  NCI scientists, along with experts from other government agencies and academic medical centers, have launched a joint effort to help FDA evaluate commercially available antibody tests for SARS-CoV-2, the coronavirus that causes COVID-19.

• 

  At NCI, A Robust and Rapid Response to the COVID-19 Pandemic

  NCI is lending its tremendous expertise and unique research capabilities to the global response to the COVID-19 pandemic. NCI Director Dr. Norman Sharpless describes some of the COVID-19 specific research activities NCI has initiated.

• 

  Cancer Research Training in the Era of COVID-19

  The director of NCI’s Center for Cancer Training, Dr. Oliver Bogler, addresses grantees about cancer research training during this unprecedented time. He advises the cancer research community to follow NIH/NCI grants guidance and suggests ideas for how grantees and trainees can use their time.

• 

  NCI Funding during the COVID-19 Public Health Emergency

  NCI Director Dr. Norman E. Sharpless addresses the grantee community about NCI funding and operations during the COVID-19 public health emergency. Dr. Sharpless highlights NCI’s peer review schedule, our program staff, as well as general NCI grants administration processes during this time.

• 

  NCI statement on clinical trials during COVID-19 pandemic

  Statement from the National Cancer Institute providing information regarding treatment of cancer patients and participation in clinical trials during the COVID-19 pandemic.

Multimedia Presentations

• Francis Collins: Home Edition Episode 10: Ned Sharpless on COVID-19 Antibody Testing

  NIH Director Dr. Francis Collins and NCI Director Dr. Ned Sharpless discuss the difference between viral and antibody testing, what antibodies tell us about the disease, why antibody tests alone are not suitable for informing back-to-workplace efforts, and NCI’s role working with FDA to test and validate SARS-CoV-2 antibody tests.

• Cancer and Other Illnesses during COVID-19: How Young Patients and Families Can Cope

  NCI hosted a YouTube Live and Facebook Live event on April 23, with experts from NCI’s Pediatric Oncology Branch and the National Institute of Mental Health to discuss coping strategies for young patients with cancer and other serious illnesses and their families on how to navigate the additional stress of the COVID-19 pandemic.

• Virtual Joint NCI Board of Scientific Advisors and National Cancer Advisory Board Meeting

  On April 9, the NCI director convened an emergency meeting of two of its key advisory boards to discuss the institute’s response to the COVID-19 pandemic.

• The director of the NCI on cancer research and clinical trials during the COVID-19 pandemic

  NCI Director Dr. Norman Sharpless joined the TheoryLab podcast to talk about how we can sustain research momentum during the pandemic, what new research opportunities have arisen, and how clinical trials have been impacted.